AUTHORS
Tracy George, MD, Lindsay Rein, MD2, Nathan Boggs, MD, PhD3, Deepti H. Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed4, Frederick Lansigan, MD5, Daniel J DeAngelo, MD, PhD6, Frank Siebenhaar, MD7, Scott R Florell, MD8, David A Wada, MD9, Cem Akin, MD, PhD10, Ingunn Dybedal, MD, PhD11, Jens Panse, MD12, Mariana C Castells, MD, PhD13, Ivan Alvarez-Twose, MD, PhD14, Stéphane Barete, MD, PhD15, Vito Sabato, MD, PhD16, Sigurd Broesby-Olsen, MD, PhD17, Hussein Ali Abbas, MD, PhD18, Lauren Madigan, MD19, Janey Scuzzarella, RN, BSN, CCRP20, Jenna Zhang, PhD21, Raheela Soomro, MD22, Karin Hartmann, MD23
AFFILIATIONS
1 University of Utah, ARUP Laboratories, Salt Lake City, Utah, United States
2 Duke Cancer Institute, Durham, North Carolina, United States
3 Uniformed Services University of the Health Sciences & Walter Reed National Military Medical Center, Bethesda, Maryland, United States
4 Guy's & St Thomas’ Hospitals NHS Foundation Trust, London, United Kingdom
5 Dartmouth Cancer Center, Lebanon, New Hampshire, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology IA, Berlin, Germany, Institute of Allergology, Charité–Universitätsmedizin Berlin, Berlin, Germany
8 University of Utah Health, Salt Lake City, Utah, United States
9 University of Utah Health, Salt Lake City, Utah, United States
10 University of Michigan, Ann Arbor, Michigan, United States
11 Oslo University Hospital, Oslo, Norway
12 Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, Aachen, Germany
13 Brigham and Women’s Hospital, Boston, Massachusetts, United States
14 Instituto de Estudios de Mastocitosis de Castilla-La Mancha, Hospital Virgen del Valle, Toledo, Spain
15 Assistance Publique-Hopitaux de Paris, CEREMAST-Pitie, Paris, France
16 Antwerp University Hospital (UZA), Edegem, Belgium
17 Odense University Hospital, Odense, Denmark
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 University of Utah Health, Salt Lake City, Utah, United States
20 Cogent Biosciences, Inc., Waltham, Massachusetts, United States
21 Cogent Biosciences, Inc., Waltham, Massachusetts, United States
22 Cogent Biosciences, Inc., Waltham, Massachusetts, United States
23 University Hospital Basel and University of Basel, Basel, Switzerland, University Hospital Basel and University of Basel, Basel, Switzerland, University Hospital Basel and University of Basel, Basel, Switzerland
ABSTRACT
Introduction
Nonadvanced systemic mastocytosis (NonAdvSM) is a rare, hematologic disorder characterized by abnormal accumulation of mast cells (MC) in multiple tissues including the bone marrow and skin. MC degranulation and mediator release can lead to debilitating clinical manifestations, including significant impact on skin that can be difficult to manage. Many patients with NonAdvSM show mastocytosis-specific cutaneous lesions that urticate spontaneously in response to various triggers, impairing patients’ quality of life. Bezuclastinib is a potent type 1 tyrosine kinase inhibitor that selectively targets KIT p.D816V, a mutated protein found in most patients with NonAdvSM. Here, we report the improvement of skin-related symptoms with bezuclastinib vs placebo and the modulation of associated MC accumulation in lesional skin in a patient subset from the Summit study.
Methods
Summit is a pivotal, multicenter, randomized, double-blind, placebo-controlled phase 2 study in patients with NonAdvSM who had inadequately controlled symptoms despite best supportive care (NCT05186753). Patients were randomized 2:1 to receive either bezuclastinib (100 mg QD) or placebo daily. After 24 weeks, patients could either continue on or crossover to bezuclastinib (100 mg QD) in an open-label extension period. Patient-reported dermatologic symptoms were assessed via the Mastocytosis Symptom Severity Daily Diary (MS2D2) patient-reported outcome measure at corresponding timepoints. Optional serial lesional skin biopsies were collected and analyzed by central pathology review at baseline and week 24 of the randomized period and after week 24 and week 48 of the open-label extension period. Patients with evaluable serial skin biopsy specimens at all timepoints were included in the analysis. MC burden and expression of CD30, a measure of aberrant MCs, were assessed in lesional biopsies at baseline and post-treatment.
Results
Of 179 patients enrolled in Summit, the subgroup with serial skin biopsies included 33 total evaluable patients in the bezuclastinib (n=23) or placebo (n=10) intention-to-treat (ITT) population. The median age (range) was 52 (24-71) years; 25 (75.8%) patients were female; and 4 patients received prior tyrosine kinase inhibitor therapy (avapritinib, 3; imatinib, 1).
The mean (SD) MS2D2 symptom severity at baseline for itching, flushing, redness, and spots was 4.8 (2.5), 4.6 (2.9), 4.9 (2.7), and 6.9 (2.1), respectively, in patients randomized to bezuclastinib and 6.2 (2.8), 5.5 (3.3), 6.0 (3.1), and 7.2 (2.3), respectively, in patients randomized to placebo. After 24 weeks of treatment, mean (SD) percent change in severity of itching, flushing, redness, and spots was -56.1% (39.0), -57.4% (35.8), -45.5% (36.7), and -42.4% (26.3), respectively, with bezuclastinib compared with -13.5% (54.5), -26.5% (49.5), -15.5% (39.2), and +0.3% (39.8), respectively, with placebo.
In lesional biopsies, 24 weeks of bezuclastinib treatment resulted in median percent change (interquartile range [IQR]) in number of MCs per mm2 of -72.6% (-91.6, -57.5), compared with -23.0% (-54.2, 39.1) with placebo. Changes in MC number in skin biopsies were comparable to the changes seen in MC burden in the bone marrow, where median percent change was -75.0% (-86.7, -53.3) with 24 weeks of bezuclastinib and 0% (-25.0, 50.0) with placebo. In patients randomized to bezuclastinib, continued treatment with bezuclastinib to 48 weeks deepened the median change in MC burden in skin biopsies to -90.7% (-96.3, -82.4). Patients who crossed over from placebo to receive 24 weeks of bezuclastinib treatment on the open-label extension had median change in skin MC burden of -85.4% (-88.8, -76.7).
At baseline, median (IQR) percentage of CD30 expression in skin biopsies was 30.0% (10.0, 60.0) in patients randomized to bezuclastinib and 30.0% (1.0, 50.0) in patients randomized to placebo. After 24 weeks of treatment, median (IQR) change in percentage of CD30 expression was -93.8% (-96.7, 0.0) with bezuclastinib and 0.0% (-50.0, 900.0) with placebo.
Conclusion
Serial skin biopsies in patients with NonAdvSM demonstrated significant improvement in underlying MC pathology with bezuclastinib vs. placebo treatment. Improvements in pathology corresponded with bezuclastinib-mediated improvements in severity of skin symptoms, suggesting substantial and clinically meaningful reduction in disease burden and parallel improvement in quality of life with bezuclastinib treatment in NonAdvSM.
DISCLOSURES
Tracy George, MD: Incyte - Consultancy (Includes expert testimony); Blueprint Medicines Corporation, a wholly owned subsidiary of Sanofi - Consultancy (Includes expert testimony); Celgene - Consultancy (Includes expert testimony); Cogent Biosciences - Consultancy (Includes expert testimony)